
AMAG Pharmaceuticals’ Makena (hydroxyprogesterone caproate) has failed to meet its co-primary endpoints in a trial of patients with a history …

GlaxoSmithKline has initiated Phase III studies to evaluate the safety and efficacy of an investigational treatment for babies born prematurely. …

Merck has offered to pay $100 million to resolve thousands of legal claims brought against it for selling a birth …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

